Table 2 Baseline patient characteristics
From: Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Number of patients | 33 |
Age at diagnosis, (range) | 51.6 (33–80) |
Female, n (%) | 23 (70) |
Race, n (%) | |
White | 20 (61) |
Black | 11 (33) |
South Asian | 1 (3) |
Middle Eastern | 1 (3) |
Non-smoker, n (%) | 17 (51.5) |
Negative TB skin test, n (%) | 31 (94) |
Negative IGRA, n (%) | 2 (6) |
Histologically proven sarcoidosis, n (%) | 33 (100) |
Pulmonary function testing* | |
FVC, % predicted | 83.4 ± 28 |
Range | 44.8–135.6 |
FEV1, % predicted | 73.5 ± 28.6 |
Range | 23.0–121.8 |
DLCO, % predicted | 57.7 ± 24.9 |
Range | 24.0–99.7 |
Immunosuppressive therapy before initiation of infliximab, n (%)** | |
Methotrexate | 27 (82) |
Azathioprine | 13 (39) |
Hydroxychloroquine | 20 (61) |
Leflunomide | 1 (3) |
Mycophenolate | 5 (15) |
IV methylprednisolone | 10 (30) |
Bronchial steroid injection | 1 (3) |
Cyclophosphamide | 4 (12) |
Rituximab | 1 (3) |